Join us for a virtual KOL event with Baudax Bio, featuring Todd M Bertoch, MD (CEO, JBR Clinical Research) and Harold S Minkowitz, MD (MD Anderson Cancer Center), discussing results from the Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.

A live question and answer session will follow the formal presentation.